SEC Form 4 · accession 0001104659-16-131423

Syros Pharmaceuticals, Inc. · SYRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

10% Owner

Period of report

Jul 6, 2016

Accepted (ET)

Jul 7, 2016 · 8:15 am EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001556263

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Jul 6, 2016	C	133,333	—	A	133,333	D
Common Stock^F1	Jul 6, 2016	C	133,333	—	A	266,666	D
Common Stock^F1	Jul 6, 2016	C	133,333	—	A	399,999	D
Common Stock^F1	Jul 6, 2016	C	531,858	—	A	931,857	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A-1 Preferred Stock^F1	—	Jul 6, 2016	C	500,000	D	—	—	Common Stock	133,333	D
Series A-2 Preferred Stock^F1	—	Jul 6, 2016	C	500,000	D	—	—	Common Stock	133,333	D
Series A-3 Preferred Stock^F1	—	Jul 6, 2016	C	500,000	D	—	—	Common Stock	133,333	D
Series B Preferred Stock^F1	—	Jul 6, 2016	C	1,994,471	D	—	—	Common Stock	531,858	D

F1The Series A-1, Series A-2, Series A-3, and Series B Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1, Series A-2, Series A-3, and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.